EC does not expect US FDA to reduce inspections during shutdown

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical drug European commission

EC: "no indication of reduced inspection activities by the FDA."
EC: "no indication of reduced inspection activities by the FDA."
The US Government shutdown is unlikely to reduce US Food and Drug Administration (FDA) inspection activity according to the European Commission.

The US Government initiated a shutdown last night​ after politicians arguing over Obamacare failed to agree a new budget. The decision will see 800,000 Federal employees - including staff of the US Food and Drug Administration (FDA) - forced to take unpaid leave and bring a halt to all non-essential activities.

How the US shutdown will impact operations at the FDA is still very much a topic of debate​, however the agency has stated that it will continue to conduct all essential activities. 

Whether these essential activities will include inspection of domestic and foreign drug ingredient production facilities is not clear, but according to the European Commission (EC) this work is likely to continue.

The Commission told in-Pharmatechnologist.com it “has had no indication of reduced inspection activities by the FDA​.”

API import waiver

Continued FDA inspections would be good news for European drugmakers that source active pharmaceutical ingredients (APIs) in the US.

Such regulatory activity is one of the reasons manufacturers in the country were granted a waiver from European import requirements introduced in July​.

If this situation changes and the US Government shutdown does hinder the FDA’s inspection activities the European Commission may reconsider the US waiver.

A Commission spokeswoman told us that: “Should such changes [to FDA inspection activities] be confirmed, the Commission will consider whether a reassessment of the country compliance with the criteria for listing is necessary.

Listed countries are expected to notify any important changes in the conditions under which the listing has been granted.​”

The UK Medicines and Healthcare products Regulatory Agency (MHRA) told this publication that “it is too early to say what the impact [of the US shutdown] will be​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars